Illumina (ILMN) is trading higher today as investors react to a fresh bullish analyst catalyst. Evercore ISI raised its price target on Illumina to $155 from $142 and kept an Outperform rating, pointing to improving end markets and a rotation setting up a “2026 Tools play.” (tipranks.com)

A higher target from a major Wall Street shop can pull incremental buyers into large-cap life-sciences tools names, especially when the rationale is macro-and-cycle oriented rather than tied to a single product launch. The Evercore thesis leans on signs of end-market stabilization and early recovery signals that could improve sentiment toward sequencing and related tools as 2026 progresses. (tipranks.com)

Illumina’s most recent formal outlook (issued with its Q4 2025 results in February 2026) guided to 2026 revenue of about $4.5B to $4.6B, operating margin of roughly 23.3% to 23.5%, and adjusted EPS of $5.05 to $5.20 (including dilution from the SomaLogic acquisition). That framework gives bulls a template for margin and earnings leverage if demand improves faster than feared. (s24.q4cdn.com)

Investors will be watching for additional analyst revisions, sequencing order trends, and any updates that validate a broader tools-cycle rebound thesis. Near-term volatility can still be driven by visibility into customer spending, geographic mix (including China), and execution on the ongoing platform transition that affects placement and consumables pull-through.